Hansa Biopharma half year report 2022

/PRNewswire/ -- Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and...

Related Keywords

Germany ,Australia ,United States ,United Kingdom ,Israel ,Italy ,Sweden ,Austria ,Spain ,Switzerland ,France ,Northern Ireland ,Craigavon ,French ,Hansa Biopharma ,Klaus Sindahl ,Hamann Girrbach ,Donato Spota ,Bristol Myers Squibb ,Guillain Barr ,Peter Nicklin ,Katja Margell ,Sciensus Ltd ,French National Authority For Health ,Transparency Commission ,Novartis ,National Institute For Health ,Tunstall Group Ltd ,Head Of Corporate Communications ,Swiss Agency For Therapeutic Products Swissmedic ,Important Service ,National Institute ,Care Excellence ,Swiss Agency ,Therapeutic Products ,French National Authority ,General Meeting ,Bayer Healthcare ,Antibody Mediated Rejection ,Novaquest Capital Management ,Investigational New Drug ,Tuesday July ,Securities Markets ,Corporate Communications ,Hansa Biopharma Ab ,